
Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report) – Analysts at HC Wainwright lowered their FY2026 earnings estimates for shares of Oruka Therapeutics in a research report issued to clients and investors on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($2.69) per share for the year, down from their previous forecast of ($2.54). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2026 earnings at ($0.74) EPS, Q1 2027 earnings at ($0.76) EPS, Q2 2027 earnings at ($0.79) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.85) EPS and FY2027 earnings at ($3.22) EPS.
A number of other equities analysts also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Mizuho set a $120.00 price objective on Oruka Therapeutics in a research report on Thursday, September 3rd. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Guggenheim reaffirmed a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a research note on Monday, October 26th. Finally, BTIG Research reiterated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $141.80.
Oruka Therapeutics Stock Up 0.3%
NASDAQ ORKA opened at $105.35 on Thursday. Oruka Therapeutics has a twelve month low of $25.23 and a twelve month high of $115.51. The stock has a 50-day moving average of $89.68 and a 200 day moving average of $72.36.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03).
Institutional Investors Weigh In On Oruka Therapeutics
Several large investors have recently bought and sold shares of ORKA. Nykredit A S purchased a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $29,000. GAMMA Investing LLC boosted its stake in shares of Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after acquiring an additional 250 shares during the last quarter. Orion Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the second quarter worth approximately $91,000. Sterling Capital Management LLC increased its position in shares of Oruka Therapeutics by 839.0% during the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock worth $138,000 after purchasing an additional 1,485 shares in the last quarter. Finally, Natural Investments LLC purchased a new stake in shares of Oruka Therapeutics during the second quarter worth approximately $202,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Oruka Therapeutics
In other news, CEO Lawrence Klein sold 25,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $95.60, for a total transaction of $2,390,000.00. Following the completion of the sale, the chief executive officer owned 923,128 shares of the company’s stock, valued at $88,251,036.80. The trade was a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kristine M. Ball sold 18,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $104.93, for a total transaction of $1,888,740.00. Following the transaction, the director owned 18,000 shares of the company’s stock, valued at approximately $1,888,740. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,950 shares of company stock worth $18,364,520 over the last three months. Company insiders own 23.49% of the company’s stock.
Key Stories Impacting Oruka Therapeutics
Here are a few of the latest stories about ORKA:
- Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
- Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
- Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing
Oruka Therapeutics Company Profile
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Read More
- Five stocks we like better than Oruka Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
